pf-04447943
Small moleculeexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2008 (NCT00736528)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2h-pyran-4-yl)-1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidin-4-one
- 6-(4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2h-pyran-4-yl)-1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidin-4-one
- pf-04447943
- pf-04447943
- pf-04447943
- pf-04447943
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02785770 | Phase 1 | Jun 1, 2016 | Pfizer |
| NCT02114203 | Phase 1 | Dec 1, 2014 | Pfizer |
| NCT01097876 | Phase 1 | Apr 1, 2010 | Pfizer |
| NCT00988598 | Phase 1 | Oct 1, 2009 | Pfizer |
| NCT00930059 | Phase 2 | Sep 1, 2009 | Pfizer |
| NCT00959803 | Phase 1 | Aug 1, 2009 | Pfizer |
| NCT00886093 | Phase 1 | Apr 1, 2009 | Pfizer |
| NCT00832052 | Phase 1 | Jan 1, 2009 | Pfizer |
| NCT00736528 | Phase 1 | Aug 1, 2008 | Pfizer |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 9 | 9 | 2 | 2008 |
1 organizations
Page 1 / 1